- Details
- Andrea Miyahira hosts Jean Tien to discuss research on CDK12 in prostate cancer. Dr. Tien demonstrates that CDK12, a transcription-associated kinase mutated in approximately 7% of metastatic prostate cancers, functions as a tumor suppressor gene. Using mouse models, she shows CDK12 deletion leads to prostate hyperplasia and high-grade PIN lesions, with CDK12-null organoids displaying increased pro...
|
- Details
- Zachary Klaassen speaks with Jack Andrews about his team's research on PSMA-positive extracellular vesicles (EVs) as biomarkers in oligometastatic prostate cancer. Dr. Andrews explains their Clinical Cancer Research publication examining plasma samples from the ORIOLE trial and STOMP-protocol patients to evaluate whether these tumor-derived particles could identify which patients benefit from ster...
|
- Details
- Andrea Miyahira speaks with Brad Gallent about a paper on the structural biology of ONECUT2, a transcription factor highly expressed in advanced prostate cancer. Dr. Gallent presents work revealing the first crystal structure of ONECUT2, showing how its CUT and HOX subdomains function together to create high-affinity DNA binding. Through isothermal titration calorimetry and mutation studies, Dr. G...
|
- Details
- Andrea Miyahira speaks with Marina Sharifi about high-purity circulating tumor cell (CTC) RNA sequencing in prostate cancer. Dr. Sharifi describes a high-stringency CTC isolation approach that achieves tissue biopsy-comparable tumor purity from just a tablespoon of blood, enabling comprehensive transcriptional profiling to identify distinct lineage states. The multi-institutional study of 70 patie...
|
- Details
- Neeraj Agarwal speaks with Umang Swami about treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Swami presents encouraging findings from a large retrospective study using the Flatiron Health database of 14,000 patients showing that ADT intensification therapies have risen dramatically from just 40% a few years ago to 77% since January 2023. The data reveals that approx...
|
- Details
- Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a retrospective chart review showing that approximately two-thirds of patients had no documented PSA doubling time, despite it being a crucial risk stratification factor. Among physicians who did docum...
|
- Details
- Zachary Klaassen interviews Alessio Crippa about the prognostic value of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer from the ProBio trial. Dr. Crippa explains how this adaptive platform trial uses non-invasive liquid biopsies to characterize patients' tumor genetic profiles, guiding treatment randomization. Their recent European Urology Oncology publication de...
|
- Details
- Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the Spanish cohort of the ARAMIS trial after progression to metastatic castration-resistant prostate cancer (mCRPC). From the 85 evaluable patients, he highlights several key findings: 29% received no fu...
|
- Details
- Neeraj Agarwal speaks with Hannah McManus about research from the IRONMAN registry examining PSA responses and outcomes in metastatic hormone-sensitive prostate cancer patients. Dr. McManus discusses findings from over 1,300 real-world patients across four countries receiving different treatment regimens. The study reveals that patients achieving undetectable PSA nadirs ( 50%) observed in the ADT...
|
- Details
- Neeraj Agarwal discusses with Yeonjung Jo and Umang Swami research comparing time from medication order to administration of cabazitaxel versus lutetium-177 in mCRPC patients. Using the Flatiron Health database of 2,329 medication orders, they found significantly longer delays for lutetium (median 22 days) compared to cabazitaxel (median 7 days). This disparity exists across both academic and comm...
|
